 Kala Pharmaceuticals has had a torrid time growing sales of its first approved ocular therapy Inveltys, for postoperative pain, which earned just 6.1m in FY20. In October last year, Kala won approval for Eysuvis, a corticosteroid treatment for short-term symptoms of dry eye disease - sales could be anything from 350m to 1bn. 